Dr. David R. Lesch, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 213
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
GA license 031968 -
Sleep Medicine (Psychiatry & Neurology) Physician
GA license 031968
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 213
- Services billed
- 1,938
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 241 | 152 |
| Established patient office or other outpatient visit, 20-29 minutes | 150 | 110 |
| Assessment of emotional or behavioral problems | 67 | 33 |
| New patient office or other outpatient visit, 60-74 minutes | 57 | 57 |
| Established patient office or other outpatient visit, 40-54 minutes | 41 | 33 |
| Measurement of brain wave activity (eeg), awake and drowsy | 34 | 33 |
| New patient office or other outpatient visit, 45-59 minutes | 28 | 28 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 20 | 18 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 19 | 18 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Suwanee, GA | 227 |
| Memantine Hcl Other prescribers in Suwanee, GA | 158 |
| Donepezil Hcl Other prescribers in Suwanee, GA | 154 |
| Escitalopram Oxalate Other prescribers in Suwanee, GA | 84 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Suwanee, GA | 83 |
| Propranolol Hcl Er (propranolol hcl) Other prescribers in Suwanee, GA | 73 |
| Levetiracetam Other prescribers in Suwanee, GA | 69 |
| Divalproex Sodium Other prescribers in Suwanee, GA | 66 |
| Lamotrigine Other prescribers in Suwanee, GA | 59 |
| Divalproex Sodium Er (divalproex sodium) Other prescribers in Suwanee, GA | 59 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $18,942 in research payments for these studies, mostly to the institutions running them.
- An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
Novartis Pharmaceuticals Corporation - A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. · Completed · NCT04244175 - A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment …
Novartis Pharmaceuticals Corporation - A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate …
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.